1. The safety and immunogenicity of a CETP vaccine in healthy adults
- Author
-
Una S. Ryan, Kevin Maki, Alistair Wheeler, Michael H. Davidson, Charles W. Rittershaus, and Denise Umporowicz
- Subjects
medicine.medical_treatment ,Dose-Response Relationship, Immunologic ,chemistry.chemical_compound ,Double-Blind Method ,Cholesterylester transfer protein ,medicine ,Humans ,Autoantibodies ,Glycoproteins ,Vaccines, Synthetic ,biology ,Cholesterol ,business.industry ,Immunogenicity ,Cholesterol, HDL ,Autoantibody ,Immunotherapy ,Cholesterol Ester Transfer Proteins ,carbohydrates (lipids) ,Clinical trial ,Dose–response relationship ,chemistry ,Immunology ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Cholesterol Esters ,Antibody ,Cardiology and Cardiovascular Medicine ,business ,Carrier Proteins - Abstract
A cholesterol ester transfer protein (CETP) vaccine (CETi-1) that induces auto-antibodies that specifically bind and inhibit activity of endogenous CETP has been demonstrated in rabbits to significantly increase HDL-C and reduce the development of atherosclerosis. In a Phase I human trial with CETi-1, one patient at the highest dose (250 mg) out of a total of 36 patients who received a single injection developed anti-CETP antibodies. In an extension study of 23 patients, 53% (8/15) who received a second injection of the active vaccine developed anti-CETP antibodies compared with 0% (0/8) in the placebo group. The vaccine was well tolerated and no significant laboratory abnormalities occurred. CETi-1 is a feasible therapy in humans to induce CETP auto-antibodies. Future research will determine if repeat inoculations will induce a sufficient anti-CETP antibody response to inhibit CETP and increase HDL levels.
- Published
- 2003